Hotovost/akcie společnosti Neovacs S.A
Jaká je hodnota metriky Hotovost/akcie společnosti Neovacs S.A?
Hodnota metriky Hotovost/akcie společnosti Neovacs S.A. je 0.02
Jaká je definice metriky Hotovost/akcie?
Účetní hodnota akcie (Book/Share) se rovná majetku společnosti minus závazky společnosti dělené počtem vydaných akcií.
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Hotovost/akcie společností v sektoru Health Care sektor na EURONEXT ve srovnání se společností Neovacs S.A
Čemu se věnuje společnost Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Firmy s metrikou hotovost/akcie podobnou společnosti Neovacs S.A
- Hodnota metriky Hotovost/akcie společnosti ELL Environmental je 0.02
- Hodnota metriky Hotovost/akcie společnosti Jervois Mining je 0.02
- Hodnota metriky Hotovost/akcie společnosti Graphite One je 0.02
- Hodnota metriky Hotovost/akcie společnosti Juniper II je 0.02
- Hodnota metriky Hotovost/akcie společnosti AMCI Acquisition je 0.02
- Hodnota metriky Hotovost/akcie společnosti Newborn Acquisition je 0.02
- Hodnota metriky Hotovost/akcie společnosti Neovacs S.A je 0.02
- Hodnota metriky Hotovost/akcie společnosti Saville Resources je 0.02
- Hodnota metriky Hotovost/akcie společnosti Coolpad je 0.02
- Hodnota metriky Hotovost/akcie společnosti Mexican Gold Mining je 0.02
- Hodnota metriky Hotovost/akcie společnosti Volt je 0.02
- Hodnota metriky Hotovost/akcie společnosti McLeod Russel India je 0.02
- Hodnota metriky Hotovost/akcie společnosti Hao Tian International Construction Investment je 0.02